DK3337477T3 - Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent - Google Patents
Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent Download PDFInfo
- Publication number
- DK3337477T3 DK3337477T3 DK16756763.5T DK16756763T DK3337477T3 DK 3337477 T3 DK3337477 T3 DK 3337477T3 DK 16756763 T DK16756763 T DK 16756763T DK 3337477 T3 DK3337477 T3 DK 3337477T3
- Authority
- DK
- Denmark
- Prior art keywords
- phosphoinositide
- compositions
- kinase inhibitors
- antiproliferative agent
- antiproliferative
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1514760.6A GB201514760D0 (en) | 2015-08-19 | 2015-08-19 | Compounds and method of use |
| PCT/GB2016/052575 WO2017029517A1 (en) | 2015-08-19 | 2016-08-19 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3337477T3 true DK3337477T3 (en) | 2023-02-20 |
Family
ID=54258859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16756763.5T DK3337477T3 (en) | 2015-08-19 | 2016-08-19 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10668077B2 (enExample) |
| EP (1) | EP3337477B1 (enExample) |
| JP (1) | JP2018523689A (enExample) |
| KR (1) | KR20180064387A (enExample) |
| CN (2) | CN113786409B (enExample) |
| AU (1) | AU2016307885B2 (enExample) |
| CA (1) | CA2995898A1 (enExample) |
| DK (1) | DK3337477T3 (enExample) |
| ES (1) | ES2939815T3 (enExample) |
| FI (1) | FI3337477T3 (enExample) |
| GB (1) | GB201514760D0 (enExample) |
| HR (1) | HRP20230376T1 (enExample) |
| HU (1) | HUE061615T2 (enExample) |
| IL (1) | IL257499A (enExample) |
| LT (1) | LT3337477T (enExample) |
| MX (1) | MX2018001926A (enExample) |
| PL (1) | PL3337477T3 (enExample) |
| PT (1) | PT3337477T (enExample) |
| RS (1) | RS64095B1 (enExample) |
| SI (1) | SI3337477T1 (enExample) |
| SM (1) | SMT202300063T1 (enExample) |
| WO (1) | WO2017029517A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200007B2 (en) | 2009-08-20 | 2015-12-01 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| WO2020055840A1 (en) * | 2018-09-11 | 2020-03-19 | Curis Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| EP3854397A4 (en) * | 2018-09-18 | 2022-07-13 | Kabushiki Kaisha Yakult Honsha | COMBINATION OF CANCER THERAPY USING QUINOLINECARBOXAMIDE DERIVATIVE |
| WO2020174420A1 (en) * | 2019-02-27 | 2020-09-03 | Astrazeneca Ab | Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor |
| CN111904958B (zh) * | 2019-05-09 | 2022-09-13 | 浙江大学 | Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用 |
| GB201909468D0 (en) * | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| WO2022105836A1 (en) * | 2020-11-19 | 2022-05-27 | Guangzhou Healthquest Pharma Co., Ltd. | Combination therapies for treating cancer |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| BE786081A (fr) * | 1971-07-13 | 1973-01-10 | Uniroyal Sa | Appareil et procede pour maintenir les tringles des bourrelets de pneu |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| CN1250294A (zh) * | 1999-07-27 | 2000-04-12 | 邮电部武汉邮电科学研究院 | 以太网与同步数字体系或同步光网络融合的适配方法 |
| ES2310166T3 (es) | 1999-08-03 | 2009-01-01 | Lilly Icos Llc | Composicion farmaceutica que contiene tadalafil. |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| ATE503743T1 (de) | 2000-04-27 | 2011-04-15 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
| US6635640B2 (en) | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP2277867B1 (en) | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in treating cancer |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1724267B1 (en) | 2004-02-26 | 2013-11-06 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| CA2567883A1 (en) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| EP2354139A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| JP2009523812A (ja) | 2006-01-19 | 2009-06-25 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 融合へテロ二環式キナーゼ阻害剤 |
| KR20090021155A (ko) | 2006-04-26 | 2009-02-27 | 에프. 호프만-라 로슈 아게 | Ｐｉ3ｋ 억제제로서의 피리미딘 유도체 |
| EP2046799B1 (en) | 2006-04-26 | 2017-07-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| ATE510840T1 (de) | 2006-06-26 | 2011-06-15 | Ucb Pharma Sa | Kondensierte thiazol-derivate als kinasehemmer |
| CN101501035B (zh) * | 2006-08-08 | 2013-01-23 | 中外制药株式会社 | 作为pi3k抑制剂的嘧啶衍生物及其用途 |
| CA2669399A1 (en) | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| US20080312199A1 (en) | 2006-12-15 | 2008-12-18 | Glinsky Gennadi V | Treatments of therapy resistant diseases and drug combinations for treating the same |
| CA2677096A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| EP2139332A4 (en) | 2007-03-28 | 2010-04-21 | Merck Sharp & Dohme | SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| EP2205242B1 (en) * | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| US20110201608A1 (en) | 2008-08-05 | 2011-08-18 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and use thereof as medicines |
| US20110257170A1 (en) | 2008-10-03 | 2011-10-20 | Merck Serono Sa | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2011012883A1 (en) | 2009-07-29 | 2011-02-03 | Karus Therapeutics Limited | Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| US9200007B2 (en) * | 2009-08-20 | 2015-12-01 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| CN101849934B (zh) * | 2010-05-25 | 2011-11-09 | 苏州大学 | 一种磷脂酰肌醇-3-激酶抑制剂及其应用 |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| JP5427321B2 (ja) | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | ２−（２，４，５−置換−アニリノ）ピリミジン化合物 |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| EP2922851B8 (en) | 2012-11-20 | 2017-09-27 | F. Hoffmann-La Roche AG | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| ES2688815T3 (es) | 2013-05-10 | 2018-11-07 | Karus Therapeutics Limited | Inhibidores de histona desacetilasa novedosos |
| SG10201709926VA (en) * | 2013-05-30 | 2017-12-28 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| ES2929576T3 (es) | 2013-10-08 | 2022-11-30 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama |
| ES2818933T3 (es) | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| GB201514756D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
-
2015
- 2015-08-19 GB GBGB1514760.6A patent/GB201514760D0/en not_active Ceased
-
2016
- 2016-08-19 EP EP16756763.5A patent/EP3337477B1/en active Active
- 2016-08-19 CN CN202111104917.2A patent/CN113786409B/zh active Active
- 2016-08-19 HU HUE16756763A patent/HUE061615T2/hu unknown
- 2016-08-19 MX MX2018001926A patent/MX2018001926A/es unknown
- 2016-08-19 KR KR1020187007564A patent/KR20180064387A/ko not_active Withdrawn
- 2016-08-19 LT LTEPPCT/GB2016/052575T patent/LT3337477T/lt unknown
- 2016-08-19 CA CA2995898A patent/CA2995898A1/en not_active Abandoned
- 2016-08-19 ES ES16756763T patent/ES2939815T3/es active Active
- 2016-08-19 PL PL16756763.5T patent/PL3337477T3/pl unknown
- 2016-08-19 SI SI201631666T patent/SI3337477T1/sl unknown
- 2016-08-19 US US15/753,353 patent/US10668077B2/en active Active
- 2016-08-19 JP JP2018508757A patent/JP2018523689A/ja not_active Withdrawn
- 2016-08-19 RS RS20230255A patent/RS64095B1/sr unknown
- 2016-08-19 PT PT167567635T patent/PT3337477T/pt unknown
- 2016-08-19 DK DK16756763.5T patent/DK3337477T3/da active
- 2016-08-19 AU AU2016307885A patent/AU2016307885B2/en not_active Ceased
- 2016-08-19 FI FIEP16756763.5T patent/FI3337477T3/fi active
- 2016-08-19 CN CN201680057437.6A patent/CN108348505B/zh active Active
- 2016-08-19 HR HRP20230376TT patent/HRP20230376T1/hr unknown
- 2016-08-19 WO PCT/GB2016/052575 patent/WO2017029517A1/en not_active Ceased
- 2016-08-19 SM SM20230063T patent/SMT202300063T1/it unknown
-
2018
- 2018-02-13 IL IL257499A patent/IL257499A/en unknown
-
2020
- 2020-04-22 US US16/855,758 patent/US11291669B2/en active Active
-
2022
- 2022-03-01 US US17/684,020 patent/US12257254B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108348505A (zh) | 2018-07-31 |
| US10668077B2 (en) | 2020-06-02 |
| IL257499A (en) | 2018-07-31 |
| US12257254B2 (en) | 2025-03-25 |
| PT3337477T (pt) | 2023-03-20 |
| CN113786409B (zh) | 2024-04-02 |
| FI3337477T3 (fi) | 2023-04-27 |
| US11291669B2 (en) | 2022-04-05 |
| EP3337477B1 (en) | 2023-02-01 |
| US20180243313A1 (en) | 2018-08-30 |
| HK1251467A1 (en) | 2019-02-01 |
| GB201514760D0 (en) | 2015-09-30 |
| US20210069200A1 (en) | 2021-03-11 |
| EP3337477A1 (en) | 2018-06-27 |
| SI3337477T1 (sl) | 2023-04-28 |
| MX2018001926A (es) | 2018-06-19 |
| CN108348505B (zh) | 2021-10-12 |
| CN113786409A (zh) | 2021-12-14 |
| CA2995898A1 (en) | 2017-02-23 |
| KR20180064387A (ko) | 2018-06-14 |
| SMT202300063T1 (it) | 2023-03-17 |
| ES2939815T3 (es) | 2023-04-27 |
| RS64095B1 (sr) | 2023-04-28 |
| HRP20230376T1 (hr) | 2023-06-23 |
| AU2016307885B2 (en) | 2019-07-25 |
| JP2018523689A (ja) | 2018-08-23 |
| LT3337477T (lt) | 2023-03-10 |
| PL3337477T3 (pl) | 2023-07-03 |
| US20230066999A1 (en) | 2023-03-02 |
| HUE061615T2 (hu) | 2023-07-28 |
| WO2017029517A1 (en) | 2017-02-23 |
| AU2016307885A1 (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257499A (en) | Compounds containing as phosphoinositide 3-kinase inhibitors and a second antiproliferative factor | |
| IL257521A (en) | Compositions comprising a pi3k inhibitor and an hdac inhibitor | |
| ZA201606074B (en) | Compositions comprising a bittering agent | |
| IL263910A (en) | Pyrimidine-based antiproliferative agents | |
| IL274006A (en) | Compounds that suppress factor Xia or kallikrein and preparations containing them | |
| SMT202000442T1 (it) | Composizioni comprendenti una combinazione di ipilimumab e nivolumab | |
| PL3355990T3 (pl) | Semifluorowane związki oraz ich kompozycje | |
| DK3250656T3 (en) | Compositions comprising 1,1-difluoroethene, trifluoromethane and a third component | |
| SMT202400019T1 (it) | Composizioni farmaceutiche comprendenti un inibitore jak | |
| IL247668B (en) | Preparations that include dopa decarboxylase inhibitors | |
| SI3405178T1 (sl) | Formulacije/pripravki, ki vključujejo inhibitor btk | |
| ZA201800821B (en) | Compositions against cat allergy | |
| PT3227325T (pt) | Composições inibidoras seletivas da sinalização trans de il-6 | |
| DK3197936T3 (da) | Silanfunktionaliserede forbindelser og sammensætninger deraf | |
| IL247921A0 (en) | Glutaminase inhibitor compounds, preparations containing them and their uses | |
| IL255219A0 (en) | pde10 suppressor compounds, preparations containing them and their uses | |
| GB201614961D0 (en) | Compounds and compositions for use | |
| ZA201803212B (en) | Gelatinase inhibitors and use thereof | |
| GB201504294D0 (en) | CT-1 inhibitor | |
| GB201504298D0 (en) | CT-1 inhibitor |